Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection

Elena Kuzmanova; Marilena Spanou; Emma Leckie; Nikolai Zhelev

doi:10.3897/biodiscovery.20.e14563

Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection

Elena Kuzmanova, Marilena Spanou, Emma Leckie, Nikolai Zhelev

Cellular Medicine

Research output: Contribution to journal › Meeting abstract › peer-review

36 Downloads (Pure)

Abstract

Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.

Original language	English
Article number	e14563
Journal	Biodiscovery
Volume	20
DOIs	https://doi.org/10.3897/biodiscovery.20.e14563
Publication status	Published - 5 Jul 2017

Keywords

Thymidine kinase
tumour-associated marker
breast cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3897/biodiscovery.20.e14563Licence: CC BY

Final Published VersionFinal published version, 33.1 KBLicence: CC BY

Cite this

@article{524e073ba97645e18890c2e591f0216f,

title = "Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection",

abstract = "Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.",

keywords = "Thymidine kinase, tumour-associated marker, breast cancer",

author = "Elena Kuzmanova and Marilena Spanou and Emma Leckie and Nikolai Zhelev",

year = "2017",

month = jul,

day = "5",

doi = "10.3897/biodiscovery.20.e14563",

language = "English",

volume = "20",

journal = "Biodiscovery",

issn = "2050-2966",

publisher = "Pensoft Publishers",

}

TY - JOUR

T1 - Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection

AU - Kuzmanova, Elena

AU - Spanou, Marilena

AU - Leckie, Emma

AU - Zhelev, Nikolai

PY - 2017/7/5

Y1 - 2017/7/5

N2 - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.

AB - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.

KW - Thymidine kinase

KW - tumour-associated marker

KW - breast cancer

U2 - 10.3897/biodiscovery.20.e14563

DO - 10.3897/biodiscovery.20.e14563

M3 - Meeting abstract

SN - 2050-2966

VL - 20

JO - Biodiscovery

JF - Biodiscovery

M1 - e14563

ER -

Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this